#Celltrion
3/4 Tiffany HSIAO, Matthews Asia MATFX & MINV: Celltrion (S Korea), Ather Energy (India), MediaTek (Taiwan), Advanced Micro-Fabrication Equipment (China)
Check link for more details.
Also, AI selloff & a terrible week, French bonds, tech options, US stock-tokens OKXICE; CBRS, MANU, NVDA...
November 20, 2026 at 10:05 PM
Celltrion's OMLYCLO® Showcases Promising Results in Chronic Spontaneous Urticaria at ACAAI 2026#United_States#Phoenix#Celltrion#OMLYCLO#CT-P39
Celltrion's OMLYCLO® Showcases Promising Results in Chronic Spontaneous Urticaria at ACAAI 2026
At the ACAAI 2026 meeting, Celltrion will showcase three analyses highlighting the efficacy and quality-of-life improvements offered by OMLYCLO® in chronic spontaneous urticaria patients.
third-news.com
November 12, 2026 at 4:07 PM
Celltrion Targets Biosimilar Patent Cliff; Mirae Asset Securities Raises Target Price 25% to 350,000 Won - BigGo Finance
Celltrion Targets Biosimilar Patent Cliff; Mirae Asset Securities Raises Target Price 25% to 350,000 Won - BigGo Finance
Celltrion Targets Biosimilar Patent Cliff; Mirae Asset Securities Raises Target Price 25% to 350,000 Won  BigGo Finance
finance.biggo.com
November 11, 2026 at 6:36 AM
PDE4 inhibition at the crossroads of IBD and obesity
L.P.-B. reports consulting fees from Abbvie, Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Banook, Biomunex, BMS, Boehringher, Celltrion, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GSK, Hemay, Hikma, Iterative Health, Janssen, Lilly, LifeMine, Luzsana, Medac, Mirador, Morphic, MSD, Nordic Pharma, Novartis, Oddifact, Oncodesign Precision Medicine, Coultreon (ex-Onco3R), ONO Pharma, OSE Immunotherapeuthics, Palisade Bio, Par’Immune, Pfizer, Prometheus, Roche, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots and Vedanta; lecture fees from Abbvie, Alfasigma, Amgen, Biogen, Celltrion, Dr Falk, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSN Labs, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Takeda and Tillots; and holds stocks or stock options in Iterative Health, Oragen, Pharmanest, Biomunex and Thetis. S.H. served as a speaker, a consultant, and/or an advisory board member for AbbVie, Alfasigma, Banook, Eli Lilly, Falk Pharma, Galapagos, Janssen/Johnson & Johnson, Materia Prima (Italy), M3 Global, Pfizer, Takeda, Tillotts, WebMD Health (Medscape); and, in addition, has received travel grants from Ferring and Pharmacosmos...
www.nature.com
November 14, 2026 at 10:53 PM
Celltrion wins EU recommendation to expand Steqeyma’s pediatric indications

https://www.byteseu.com/2508165/

사진 확대 (Yonhap) South Korean biopharmaceutical company Celltrion Inc. said Monday that its biosimilar Steqeyma (CT-P43), has received a positive recommendation from the European Medicines …
Celltrion wins EU recommendation to expand Steqeyma’s pediatric indications - Bytes Europe
(Yonhap)
www.byteseu.com
November 9, 2026 at 3:52 AM
Celltrion obesity drug — World’s First Quad-Action Treatment Shows Superior Non-Clinical Results
Celltrion obesity drug — World's First Quad-Action Treatment Shows Superior Non-Clinical Results
Celltrion unveiled non-clinical results for its world-first quad-acting obesity drug candidate CT-G32, demonstrating superior weight loss effects.
en.koreadaily.com
November 4, 2026 at 5:45 AM
📉 HCA Healthcare shares slid following its third-quarter earnings call.
📊 Celltrion reported record Q3 revenue of 1.58 trillion won ($1.18B).
📉 Hanwha Ocean missed Q3 profit estimates, prompting target cuts.
October 28, 2026 at 6:47 AM
📈 Samsung Biologics and Celltrion hit record Q3 results.
📈 KOSPI rebounds above 5,600 on tech buying.
October 27, 2026 at 6:11 AM
Celltrion Skincureのヘルスケアブランド「INNERLAB」、Qoo10 Japanの「メガ割」「メガデビュー」にて連続で好調な実績を記録
Celltrion Skincureのヘルスケアブランド「INNERLAB」、Qoo10 Japanの「メガ割」「メガデビュー」にて連続で好調な実績を記録
Celltrion Skincure Co., Ltd.のプレスリリース ~代表商品「小さなダイエット カフェスリム一杯」、サプリメント・ダイエットカテゴリーでランキング1位を獲得~ Qoo10 Japan「サプリメント ...
beautypost.jp
October 26, 2026 at 4:42 AM
Kaigene and Celltrion Forge Exclusive Partnership for Innovative Antibody Therapy KG013#United_States#Rockville#Celltrion#Kaigene#KG013
Kaigene and Celltrion Forge Exclusive Partnership for Innovative Antibody Therapy KG013
Kaigene has initiated a landmark licensing agreement with Celltrion for its pioneering anti-APRIL antibody, KG013, aimed at treating autoimmune diseases.
third-news.com
October 22, 2026 at 1:38 PM
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
On October 5, 2026, Celltrion announced the U.S. launch of Omlyclo® (omalizumab-agec) as the first interchangeable biosimilar of Genentech’s...
www.jdsupra.com
October 22, 2026 at 6:27 PM
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
On October 5, 2026, Celltrion announced the U.S. launch of Omlyclo® (omalizumab-agec) as the first interchangeable biosimilar of Genentech’s...
www.jdsupra.com
October 22, 2026 at 6:27 PM
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
On October 5, 2026, Celltrion announced the U.S. launch of Omlyclo® (omalizumab-agec) as the first interchangeable biosimilar of Genentech’s...
www.jdsupra.com
October 22, 2026 at 6:27 PM
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
Biosimilar U.S. Launches: Omlyclo® the First Interchangeable Biosimilar of Xolair® and Filkri™ a Neupogen® Biosimilar
On October 5, 2026, Celltrion announced the U.S. launch of Omlyclo® (omalizumab-agec) as the first interchangeable biosimilar of Genentech’s...
www.jdsupra.com
October 22, 2026 at 6:27 PM
Celltrion Launches Omalizumab Biosimilar in the United States
Celltrion Launches Omalizumab Biosimilar in the United States
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first...
www.jdsupra.com
October 14, 2026 at 10:52 PM
Celltrion Launches Omalizumab Biosimilar in the United States
Celltrion Launches Omalizumab Biosimilar in the United States
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first...
www.jdsupra.com
October 14, 2026 at 10:52 PM
Celltrion Launches Omalizumab Biosimilar in the United States
Celltrion Launches Omalizumab Biosimilar in the United States
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first...
www.jdsupra.com
October 14, 2026 at 10:52 PM
The #FDA has expanded pediatric indications for adalimumab-aaty (Yuflyma; Celltrion USA) and unbranded adalimumab-aaty to include the treatment of hidradenitis suppurativa in adolescent patients aged 12 years and older, and uveitis in pediatric patients aged 2 years and older.
October 17, 2025 at 1:49 PM